JL

John Lambert

Amplia Therapeutics Limited | Chief Executive Officer
Dr Lambert was appointed CEO on 24 June 2019 and Managing Director on 6 February 2020. John has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, he was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry he was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.

Company and Role

Company
Title
Tenure
Since
ATX
Amplia Therapeutics Limited
  • Chief Executive Officer
5yrsJun 2019

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ATX
Amplia Therapeutics Limited
30/11/22162,500275,0001,099,168N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ATX
Amplia Therapeutics Limited
31/08/22
Expiry
750,000$0.100$75,000Options expired
ATX
Amplia Therapeutics Limited
30/06/22
Expiry
50,000$0.096$4,800Options expired
ATX
Amplia Therapeutics Limited
15/12/21
Issued
29,168$0.170$4,958Rights issue
ATX
Amplia Therapeutics Limited
15/12/21
Issued
32,500$0.180$5,850Rights issue
ATX
Amplia Therapeutics Limited
15/12/21
Issued
55,000$0.180$9,900Rights issue